These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19421773)

  • 1. Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications.
    Pradhan M; Davidson B; Tropé CG; Danielsen HE; Abeler VM; Risberg B
    Virchows Arch; 2009 Jun; 454(6):677-83. PubMed ID: 19421773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow and image cytometric DNA ploidy, including 5c exceeding cells, of serous borderline malignant ovarian tumors. Correlation with clinicopathologic characteristics.
    Flezar MS; But I; Kavalar R; Us-Krasovec M
    Anal Quant Cytol Histol; 2003 Jun; 25(3):139-45. PubMed ID: 12882085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas.
    Pradhan M; Abeler VM; Danielsen HE; Tropé CG; Risberg BA
    Mod Pathol; 2006 Sep; 19(9):1227-35. PubMed ID: 16729014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
    Bakshi N; Rajwanshi A; Patel F; Ganguly NK
    Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation.
    Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH
    BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
    Fu YS; Ro J; Reagan JW; Hall TL; Berek J
    Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.
    Lage JM; Weinberg DS; Huettner PC; Mark SD
    Cancer; 1992 Jun; 69(11):2668-75. PubMed ID: 1571896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
    Nilforoushan N; Moatamed NA
    Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
    Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
    Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
    Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
    Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome.
    Demirel D; Laucirica R; Fishman A; Owens RG; Grey MM; Kaplan AL; Ramzy I
    Cancer; 1996 Apr; 77(8):1494-500. PubMed ID: 8608534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
    Körner M; Burckhardt E; Mazzucchelli L
    J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
    Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
    Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.
    McCluggage WG; Vosmikova H; Laco J
    Int J Gynecol Pathol; 2020 Jan; 39(1):84-92. PubMed ID: 30575604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computerized image analysis and flow cytometric evaluation of ovarian borderline tumors: a study of 24 cases.
    Esposito MJ; Fuchs A
    Cytometry; 1994 Dec; 18(4):218-22. PubMed ID: 7895528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.